Research Supporting the Use of Ruxolitinib for the Treatment of Myelofibrosis
Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, discusses research supporting the use of ruxolitinib (Jakafi) for the treatment of myelofibrosis.
According to Ali, COMFORT-1 (NCT00952289) and COMFORT-2 (NCT00934544), showed that ruxolitinib showed good responses when compared to best available treatment or other supportive treatments. It was also shown beneficial for the treatment of polycythemia vera.
Ruxolitinib was recently approved for the treatment of graft versus host disease (GvHD) and has shown promise in chronic GvHD. According to Ali, this is due to the unique mechanism of improving inflammation, which is the main driver in patients with myelofibrosis, other myeloproliferative neoplasms, and GvHD.
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
November 15th 2024The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.
Read More
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
November 12th 2024In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.
Read More
